Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises GB HoldCo on its takeover bid for Gunnebo
Mandate

Vinge advises GB HoldCo on its takeover bid for Gunnebo

September 28, 2020 Banking and Finance Commercial Agreements EU, Competition and Regulatory Capital Markets and Public M&A M&A IT, Telecommunications and Outsourcing Intellectual Property

Altor Fund V and Stena Adactum AB have, through the jointly controlled company GB HoldCo AB, announced a recommended cash offer to the shareholders of Gunnebo Aktiebolag. The offer values Gunnebo at approximately SEK 2.4 billion.

Gunnebo develops, manufactures, markets and sells security products, software and services. The Company has its headquarters in Gothenburg with operations globally through own presence in approximately 25 countries. In addition, Gunnebo's products and solutions are sold in more than 100 markets through comprehensive distribution networks.

Vinge’s team consisted of David Andersson, Erik Sjöman, Amanda Knutsson and Julia Hirschberg (Capital Markets and Public M&A), Christina Kokko, Maria Dahlin Kolvik, Desirée Sjöblom, Elsie Nassar and Carl Fredrik Wachtmeister (M&A), Louise Brorsson Salomon, Linn Adelwald, Pauline Lagerstrand and Hannes Pettersson (Banking and Finance) Johan Karlsson and Johan Wahlbom (Competition law), Sofia Bergenstråhle (IP), Karl-Hugo Engdahl (IT) and Jolene Reimerson (Commercial Agreements).

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026